R Bassett

Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial

Kamaria L. Lee, Clinton Yam, Li Zhao, R Bassett et autres

PURPOSE: Most patients with triple-negative breast cancer (TNBC) undergo neoadjuvant therapy (NAT). Prospective studies on the landscape of non-BRCA germline pathogenic variants (PVs) in patients with TNBC and their impact on response to NAT are sparse. METHODS: On a prospective trial, patients …

us (code pays fourni par la source)

IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)–positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC).

Jason A. Mouabbi, Paula R. Pohlmann, Rachel M. Layman, R Bassett et autres

TPS1166 Background: ILC accounts for approximately 10–15% of breast cancers and is predominantly hormone receptor–positive (HR+)/HER2–. Patients with endocrine-refractory mILC have poor outcomes, with median progression-free survival (PFS) of less than three months following standard therapies. ILC is biologically distinct from invasive …

us (code pays fourni par la source)

Distant recurrence–free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease?

Jason A. Mouabbi, Akshara Singareeka Raghavendra, Taiwo Adesoye, Sarah Pasyar et autres

587 Background: ILC is a distinct breast cancer subtype with unique biology and clinical behavior compared with invasive ductal carcinoma. The prognostic significance of isolated tumor cells (ITCs; pN0(i+)) in ILC remains unclear, creating a management gap regarding whether patients with ITCs …

us (code pays fourni par la source)

C77-05 Incidence and Risk Factors for Pneumonitis After Check Point Inhibitor Immunotherapy in Patients With Genitourinary Cancers

F A Camacho, M C Boshkos, F Soto, S Pasyar et autres

Abstract Rationale Genitourinary cancers (GU) contribute significantly to global cancer mortality. Immune checkpoint inhibitors (ICI) have improved outcomes for patients with GU cancers. However, immune-related adverse events, including pneumonitis, can increase morbidity and mortality. Although clinical trials measure ICI-pneumonitis (ICI-P) incidence at …

us (code pays fourni par la source)

522P Safety run-in of REPLOT: Phase II repotrectinib plus fulvestrant in HR+/HER2− metastatic invasive lobular carcinoma (mILC) after endocrine therapy (ET) and CDK4/6 inhibition

J.A. Mouabbi, A. Nwosu Ilheme, K. Koenig, C Haymaker et autres

us, se (code pays fourni par la source)

608P Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity

V. Valero, A. Singareeka Raghavendra, S Pasyar, R Bassett et autres

us (code pays fourni par la source)